Trial Profile
A Phase 2b/3, Multicenter Study to Assess the Treatment Strategy of Using PRO 140 SC as Long-Acting Single-Agent Maintenance Therapy for 48 Weeks in Virologically Suppressed Subjects With CCR5-tropic HIV-1 Infection
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Sponsors CytoDyn
- 13 Jan 2022 Planned End Date changed from 1 Dec 2021 to 15 Jun 2022.
- 28 Sep 2021 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 19 Aug 2021 According to a CytoDyn media release, the company has completed a Phase 2b/3 investigative trial with leronlimab used as a once-weekly monotherapy for HIV-infected patients.